Successful combination therapy of bimekizumab and granulocyte monocyte adsorption apheresis for generalized pustular psoriasis complicated with microscopic polyangiitis

Shukuin, Rie; Koizumi, Haruka; Ebata, Aoi; Imai, Satoko; Yamashita, Yuta; Ogawa‐Momohara, Mariko; Takeichi, Takuya; Muro, Yoshinao; Takami, Norito; Akiyama, Masashi

doi:10.1111/1346-8138.16707

Cited by 5 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biologics such as inhibitors against TNFα, IL-12/23, or IL-17, Janus kinase (JAK) inhibitors and tyrosine kinase (TYK) 2 inhibitor are also effective in GPP and PsA. A combination or sequential therapy with these agents and GMA is expected to reduce adverse effects and show greater effectiveness in the future [13,14]. In this study, GMA was used sequentially with the other treatments.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment with granulocyte and monocyte adsorption apheresis for plaque‐type skin lesions in patients with psoriatic arthritis

Seishima,

Hachiken,

Furukawa

et al. 2024

Ther Apher Dial

View full text Add to dashboard Cite

IntroductionGranulocyte and monocyte adsorption apheresis (GMA) is usually performed weekly for refractory skin diseases, such as generalized pustular psoriasis and psoriatic arthritis (PsA).MethodsFour patients with PsA who were refractory to previous treatments were enrolled. They received five or ten sessions of GMA. We assessed the clinical conditions of each patient and laboratory findings before and after GMA.ResultsGMA was effective in plaque‐type skin eruptions in all four patients with PsA. It was also effective in joint symptoms in three patients with PsA with mild symptoms, but was ineffective in one patient with severe joint symptoms.ConclusionGMA may be recommended to PsA patients with skin eruptions and mild joint symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful treatment with granulocyte and monocyte adsorption apheresis for plaque‐type skin lesions in patients with psoriatic arthritis

Seishima,

Hachiken,

Furukawa

et al. 2024

Ther Apher Dial

View full text Add to dashboard Cite

show abstract

“…[117][118][119] Recently, a case of a 69-year-old Japanese woman with GPP successfully treated with bimekizumab in combination granulocyte monocyte adsorption apheresis was reported. 120…”

Section: Bimekizumabmentioning

confidence: 99%

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

Megna¹,

Camela²,

Ruggiero³

et al. 2023

CCID

View full text Add to dashboard Cite

Generalized pustular psoriasis (GPP) is a severe and rare form of psoriasis, being a potentially life-threatening condition, characterized by recurring episodes or flares of widespread cutaneous erythema with macroscopic sterile pustules. An irregular innate immune response is linked to GPP, which is considered an auto-inflammatory disorder, while innate and adaptive immunopathogenic responses are involved in psoriasis pathogenesis. In consequence, different cytokine cascades have been suggested to be mainly involved in the pathogenesis of each different psoriasis form, with the interleukin (IL)23/IL17 axis implied in plaque psoriasis, and the IL36 pathway in the GPP. As regards GPP treatment, conventional systemic drugs available for plaque psoriasis are usually used as the first-line treatment option. However, contraindications and adverse events often limit the use of these therapies. In this scenario, biologic drugs may represent a promising treatment option. To date, even if 12 different biologics have been approved for plaque psoriasis, none of these is approved for GPP where they are employed off-label. Recently, spesolimab, an anti-IL36 receptor monoclonal antibody, has been recently approved for GPP. The purpose of this article is to assess the current literature about the use of biological therapies for the treatment of GPP to establish the basis for a shared GPP management algorithm.

show abstract

“…There has only been one case in the past of the use of bimekizumab for GPP in real-world treatment. 4 We recently successfully treated two patients with GPP with bimekizumab.…”

Section: Two Cases Of Generalized Pustular Psoriasis Successfully Tre...mentioning

confidence: 99%

“…5 Similar effects of bimekizumab are anticipated in the lesions of GPP. Bimekizumab might improve the symptoms of GPP resistant to the other treatments, possibly by inhibiting the expression of molecules promoting the activation or chemotaxis of neutrophils via blocking IL-17A and IL-17F.Based on previous reports that bimekizumab was effective against GPP,4 and the evidence of that in the present case, it is possible that F I G U R E 1 Multiple sterile pustules and membranous desquamation on edematous erythema of (a) case 1 and (d) case 2. Histopathology of subcorneal spongiform pustule of Kogoj in (b) case 1 and (e) case 2 (hematoxylin-eosin, original magnification ×400).…”

mentioning

confidence: 99%

Two cases of generalized pustular psoriasis successfully treated with bimekizumab

Hagino

Saeki

Kanda

2023

The Journal of Dermatology

View full text Add to dashboard Cite

Successful combination therapy of bimekizumab and granulocyte monocyte adsorption apheresis for generalized pustular psoriasis complicated with microscopic polyangiitis

Cited by 5 publications

References 5 publications

Successful treatment with granulocyte and monocyte adsorption apheresis for plaque‐type skin lesions in patients with psoriatic arthritis

Successful treatment with granulocyte and monocyte adsorption apheresis for plaque‐type skin lesions in patients with psoriatic arthritis

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

Two cases of generalized pustular psoriasis successfully treated with bimekizumab

Contact Info

Product

Resources

About